Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Stomach Neoplasms, Date of authorisation: 19/12/...

Cyramza was found effective in patients with advanced gastric or gastro-oesophageal junction cancer, metastatic colorectal cancer, advanced or metastatic non-small cell lung cancer and hepatocellular carcinoma in 6 main studies. Gastric cancer In one main …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma;Urticaria, Date of authorisation: 25/10/2005, ...

Allergic asthma Xolair was studied in over 2,000 patients aged 12 years or over with allergic asthma in five main studies, including one involving 482 patients with severe allergic asthma that was not controlled by conventional treatments. In all the …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma;Urticaria, Date of authorisation: 25/10/2005, ...

Allergic asthma Xolair was studied in over 2,000 patients aged 12 years or over with allergic asthma in five main studies, including one involving 482 patients with severe allergic asthma that was not controlled by conventional treatments. In all the …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Amyloidosis, Date of authorisation: 16/11/2011, ...

In patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily. The broken protein forms a fibrous substance called amyloid that is deposited in tissues and organs around the body, including around nerves, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Amyloidosis, Date of authorisation: 16/11/2011, ...

In patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily. The broken protein forms a fibrous substance called amyloid that is deposited in tissues and organs around the body, including around nerves, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Breast Neoplasms, Date of authorisation: 10/06/2008, ...

Tyverb in combination with another cancer medicine was shown to be more effective than the comparator treatment in three main studies involving women with breast cancer. In all the studies, the main measure of effectiveness was how long the patients lived …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Breast Neoplasms, Date of authorisation: 10/06/2008, ...

Tyverb in combination with another cancer medicine was shown to be more effective than the comparator treatment in three main studies involving women with breast cancer. In all the studies, the main measure of effectiveness was how long the patients lived …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Revestive, teduglutide, Malabsorption Syndromes, Date of authorisation: ...

The active substance in Revestive, teduglutide, is similar to human glucagon-like peptide 2 (GLP‑2), a hormone made in the gut that increases absorption of nutrients from the intestine. Teduglutide works in a similar way to GLP-2 and increases intestinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Revestive, teduglutide, Malabsorption Syndromes, Date of authorisation: ...

The active substance in Revestive, teduglutide, is similar to human glucagon-like peptide 2 (GLP‑2), a hormone made in the gut that increases absorption of nutrients from the intestine. Teduglutide works in a similar way to GLP-2 and increases intestinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Arthroplasty, Replacement;Venous Thromboembolism, ...

Treatment and prevention of DVT and pulmonary embolism For DVT and pulmonary embolism, Xarelto was compared with enoxaparin (another anticoagulant medicine) given in combination with a vitamin K antagonist, VKA (a class of anticoagulants such as warfarin), …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Arthroplasty, Replacement;Venous Thromboembolism, ...

Treatment and prevention of DVT and pulmonary embolism For DVT and pulmonary embolism, Xarelto was compared with enoxaparin (another anticoagulant medicine) given in combination with a vitamin K antagonist, VKA (a class of anticoagulants such as warfarin), …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Copanlisib, decision type: , therapeutic area: , PIP number: P/0385/...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:22 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq,Upadacitinib (ABT-494), decision type: , therapeutic area: , PIP ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro,Lanadelumab (DX-2930), decision type: , therapeutic area: , ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan,hydrochlorothiazide, Hypertension, Date of ...

Ifirmacombi contains two active substances, irbesartan and hydrochlorothiazide. Irbesartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan,hydrochlorothiazide, Hypertension, Date of ...

Ifirmacombi contains two active substances, irbesartan and hydrochlorothiazide. Irbesartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Tabula Rasa HealthCare’s Newly Acquired Subsidiary, Mediture, Expands Managed Long-term Care Services with Visiting Nurse Service ...

MOORESTOWN, N.J., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today announced its subsidiary, Mediture, is expanding services in a new …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on September 17, 2018 - 12:21 GMT

Human medicines European public assessment report (EPAR): Ceplene, histamine dihydrochloride, Leukemia, Myeloid, Acute, Date of ...

Ceplene is a medicine used in combination with interleukin-2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used during the patients’ first ‘remission’ (a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Human medicines European public assessment report (EPAR): Lacosamide Accord, lacosamide, Epilepsy, Date of authorisation: 18/09/...

Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. Lacosamide Accord is indicated as adjunctive therapy …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:21 GMT

Human medicines European public assessment report (EPAR): Lacosamide Accord, lacosamide, Epilepsy, Date of authorisation: 18/09/...

Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. Lacosamide Accord is indicated as adjunctive therapy …

Distribution channels: Healthcare & Pharmaceuticals Industry